Breaking News
Upgrade 0
🚀 5 new AI-picked strategies for US stocks beating the market in healthcare, energy & more
Learn more
Close

T. Rowe Price Health Sciences Fund I Class (THISX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
85.26 +0.35    +0.41%
17/10 - Closed. Currency in USD
Type:  Fund
Market:  United States
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 4.86B
T. Rowe Price Health Sciences I 85.26 +0.35 +0.41%

THISX Overview

 
On this page you'll find an in-depth profile of T. Rowe Price Health Sciences Fund I Class. Learn about the key management, total assets, investment strategy and contact information of THISX among other information.
Category

Health

Total Assets

4.86B

Expenses

0.68%

Inception Date

42452

Contact Information

Address The Gate, Level 15, Office 24
Dubai,Dubai XXXXXX
United Arab Emirates
Phone 971 4 4019266

Top Executives

Name Title Since Until
Ziad Bakri Equity Research Analyst 2016 Now
Biography Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban
Jason(Jay) Nogueira Portfolio Manager 2025 2025
Biography Jay Nogueira is the head of Global Equity Research, a member of the Global Equity Steering Committee, and chair of the Process and Innovation Subcommittee and the Equity Research Advisory Committee in the Equity Division. He is a co-portfolio manager of the US Structured Research Equity Strategy, cochairman of the US Structured Research Equity Strategy's Investment Advisory Committee, and a member of the portfolio oversight team. Additionally, Jay is a member of the oversight team for the International and Global Structured Research Equity Strategies. He is a vice president of T. Rowe Price Group, Inc. Jay's investment experience began in 2001, and he has been with T. Rowe Price since 2004, beginning as an investment analyst covering health care services in the U.S. Equity Division. He subsequently became associate portfolio manager for the Global Growth Equity Strategy. In 2015, Jay became the sector portfolio manager of the Global Consumer Equity Strategy, which he incepted that year as the sector team lead. He also had portfolio management responsibilities for the US Structured Research Equity Strategy, both as an analyst and as a sector portfolio manager. Most recently, Jay was director of equity research for North America in the U.S. Equity Division. Prior to T. Rowe Price, Jay was employed by Putnam Investments as a health care equity analyst. Jay also was a leveraged buyout analyst at J.W. Childs Associates and an investment banking analyst at Goldman, Sachs & Company prior to business school. Jay earned an S.B. in mechanical engineering from the Massachusetts Institute of Technology, where he was a member of Phi Beta Kappa, and an M.B.A., with high distinction, from Harvard Business School, where he was designated a Baker Scholar, a Siebel Scholar, and a Ford Scholar. Jay also has earned the Chartered Financial Analyst® designation. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Taymour R. Tamaddon Portfolio Manager 2013 2016
Biography Taymour R. Tamaddon is a vice president of T. Rowe Price Group, Inc. and T. Rowe Price Associates, Inc. He is also a vice president of the T. Rowe Price Institutional International Funds, Inc., and the T. Rowe Price International Funds, Inc. He joined the firm in 2004 after serving as a summer intern with T. Rowe Price in 2003, covering the eye care industry. Prior to this, Taymour was employed by Amazon.com in the areas of finance and merchandizing. He was also a consultant with Booz Allen and Hamilton, specializing in the energy industry.
Kris H. Jenner Chairman 2000 2013
Biography Mr. Jenner has been chairman of the committee since2000.He is a lead portfolio manager and a VP of T. Rowe Price Group. Dr. Jenner joined T. Rowe in 1997 as a health care sector analyst and now acts as its lead analyst for biotechnology and US pharmaceutical companies. He has also been portfolio manager for the Oxford Capital Group, where he managed a private hedge fund specializing in health care. Dr. Jenner graduated summa cum laude and as a member of Phi Beta Kappa from the University of Illinois with a B.S. in Chemistry. He received a D. Phil. from University of Oxford.
Laurie Mundt Research Analyst 2007 2007
Biography Prior to joining Fidelity Investments in 2008 as a research analyst, Ms. Mundt served as a vice president for T. Rowe Price Group, which she joined in 2000.
Brian Stansky Vice President, Investment Analyst 1998 2000
Biography Stansky is a vice president with T. Rowe Price Associates, his employer since 1989. He also serves as an investment analyst in the firm's equity research division. Previously, he worked as a financial analyst with Honeywell Information Systems. Stansky is a Chartered Financial Analyst.
Joseph Klein Vice President 1995 1998
Biography Joseph Klein is a Portfolio Manager for the Hightower Equity SMA strategies. He is responsible for the quantitative modeling and leads portfolio construction decisions made throughout the investment process. Joe has seven years of investment related experience and was previously a Leveraged Finance Credit Analyst for Barclays, where he covered health care and industrial companies. Joe also spent time as a Restructuring Senior Associate for Ankura Consulting Group, where he advised the Government of Puerto Rico in 2017-2018. Joe graduated from New York University’s Stern School of Business. Joe holds the FINRA Series 7 & 63 licenses. Outside of work, Joe interests include real estate, softball, and urban gardening. He is a lifelong New Yorker.
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

THISX Comments

Write your thoughts about T. Rowe Price Health Sciences Fund I Class
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email